rituximab,cyclophosphamide
biogen,roche
[]
recital trial: first line rtx vs. cyc in ild asso w/ ssc, mixed ctd or myositis.
primart endpoint fvc 24 wks improved in both mctd and myositis associated ild but only stabilized in ssc-ild. rtx improved skin thickness 24 wks. abst#0003 #acr22 
MD, PhD Institute of Infection and Immunity @UofGlasgow UK. Past Co-chair of @EULAR Synovitis Study Group. CrossFit athlete and Mountains lover. Views my own.